| Old Articles: <Older 22781-22790 Newer> |
|---|
 |
The Motley Fool
April 30, 2007
Tom Taulli |
Proxy Fights 101 How shareholder skirmishes are transforming Wall Street. It's smart to understand how proxy fights work, but don't assume they're a good system for investing. Proxy battles often target struggling companies with volatile stocks.   |
The Motley Fool
April 30, 2007
Mike Cianciolo |
Playing It Safe at Safeway The grocery chain's strong earnings and sales weren't enough for management to increase guidance for the year. Investors, take note. |
The Motley Fool
April 30, 2007
Rick Aristotle Munarriz |
Xinhua's X Factor The Chinese media company posts good -- but not great -- results. Even after today's pop, the stock is still trading well below its IPO price. |
The Motley Fool
April 30, 2007
David Meier |
It Pays to Be Different There's plenty not to like about these retailers. Should investors be looking to buy? Big Dog Holdings... Pep Boys... Wild Oats... etc. |
The Motley Fool
April 30, 2007
Anders Bylund |
Foolish Forecast: Bumbling Blockbuster The movie rental retailer is set to report its first-quarter 2007 earnings. Investors, here is what you can expect to see. |
The Motley Fool
April 30, 2007
Anders Bylund |
Breakfast With Kellogg's: Fool by Numbers The breakfast food expert released first-quarter 2007 earnings: Income Statement Highlights... Margin Checkup... Balance Sheet Highlights... Cash Flow Highlights... |
The Motley Fool
April 30, 2007
Toby Shute |
Valero: Hooked on Crack Spreads Valero depends on them to earn its outsized profits. With gasoline inventories low, business is booming. These high spread levels can't last indefinitely -- so investors need to be careful with this refiner group. |
The Motley Fool
April 30, 2007
Tom Taulli |
McAfee's CEO Blogs for Bucks Whether or not DeWalt had anything to do with the rise in McAfee's shares, this software veteran will likely help the company grab its share of the continued growth in security software. |
The Motley Fool
April 30, 2007
Seth Jayson |
Bad Brew at FEMSA The Mexican company does OK with Coke, but the brew biz was botched. Investors, take note. |
The Motley Fool
April 30, 2007
Brian Lawler |
Alexion Heads Overseas Alexion is headed for approval of its lead compound in the European Union. With no other compounds in clinical stage development, an investment in Alexion is all about the market potential for Soliris. |
| <Older 22781-22790 Newer> Return to current articles. |
